Latin American women’s experiences with medical abortion in settings where abortion is legally restricted

Reproductive Health

Silvina Ramos³  Mariana Romero²  Nina Zamberlin¹ 

[1] Center for the Study of State and Society (CEDES) (External Researcher) and Adolescent Health Foundation (FUSA), Buenos Aires, Argentina;Center for the Study of State and Society and National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina;Center for the Study of State and Society, Buenos Aires, Argentina

关键词: Latin America;    Misoprostol;    Medical abortion;   

Others  :  811912
DOI  :  10.1186/1742-4755-9-34

 received in 2012-08-23, accepted in 2012-12-07,  发布年份 2012

【 摘 要 】

Abortion is legally restricted in most of Latin America where 95% of the 4.4 million abortions performed annually are unsafe.

Medical abortion (MA) refers to the use of a drug or a combination of drugs to terminate pregnancy. Mifepristone followed by misoprostol is the most effective and recommended regime. In settings where mifepristone is not available, misoprostol alone is used.

Medical abortion has radically changed abortion practices worldwide, and particularly in legally restricted contexts. In Latin America women have been using misoprostol for self-induced home abortions for over two decades.

This article summarizes the findings of a literature review on women’s experiences with medical abortion in Latin American countries where voluntary abortion is illegal.

Women’s personal experiences with medical abortion are diverse and vary according to context, age, reproductive history, social and educational level, knowledge about medical abortion, and the physical, emotional, and social circumstances linked to the pregnancy. But most importantly, experiences are determined by whether or not women have the chance to access: 1) a medically supervised abortion in a clandestine clinic or 2) complete and accurate information on medical abortion. Other key factors are access to economic resources and emotional support.

Women value the safety and effectiveness of MA as well as the privacy that it allows and the possibility of having their partner, a friend or a person of their choice nearby during the process. Women perceive MA as less painful, easier, safer, more practical, less expensive, more natural and less traumatic than other abortion methods. The fact that it is self-induced and that it avoids surgery are also pointed out as advantages. Main disadvantages identified by women are that MA is painful and takes time to complete. Other negatively evaluated aspects have to do with side effects, prolonged bleeding, the possibility that it might not be effective, and the fact that some women eventually need to seek medical care at a hospital where they might be sanctioned for having an abortion and even reported to the police.

【 授权许可】

   
2012 Zamberlin et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]World Health Organization: Unsafe abortion: global and regional estimates of the incidence of unsafe abortion and associated mortality in 2008. 6th edition. Geneva; 2011.
• [2]Guttmacher Institute: Facts on abortion in Latin America and the Caribbean January 2012. http://www.guttmacher.org/pubs/fb_IAW.pdf webcite
• [3]Grimes DA: Reducing the complications of unsafe abortion: The role of medical technology. In Preventing Unsafe Abortion and its Consequences: Priorities for Research and Action. Edited by Warriner IK, Shah IH. New York: Guttmacher Institute; 2006:73-91.
• [4]Espinoza H, Ellertson C, García S, Schiavon R, Langer A: Medicamentos para la interrupción de la gestación: una revisión de la literatura y sus posibles implicaciones para México y América Latina. Gac Med Mex 2002, 138:347-356.
• [5]Kumara A, Hessini L, Mitchell E: Conceptualising abortion stigma. Cult Health Sex 2009, 11:625-636.
• [6]Singh S, Prada E, Kestler E: Induced abortion and unintended pregnancy in Guatemala. Int Fam Plan Perspect 2006, 32:136-145.
• [7]Gynuity Health Projects: Providing medical abortion in low-resource settings: An introductory guidebook. 2nd edition. New York: Gynuity Heath Projects; 2009.
• [8]World Health Organization: Safe Abortion: Technical and Policy Guidance for Health Systems – 2nd edition. 2012.
• [9]IPAS-CLACAI: Misoprostol y Aborto con Medicamentos en Latinoamérica y el Caribe. Lima; 2010.
• [10]Pollack AE, Pine RN: Opening a door to safe abortion: international perspectives on medical abortifacient use. J Am Med Women’s Assoc 2000, 55(Suppl 3):186-188.
• [11]Barbosa R, Arilha M: The Brazilian experience with Cytotec. Stud Fam Plann 1993, 24:236-240.
• [12]Diniz D, Corrêa M: Aborto e Saúde Pública 20 Anos de Pesquisas no Brasil. Brasília: Ministerio da Saude; 2008.
• [13]Faundes A: O uso do misoprostol no Brasil. In Aborto Medicamentoso no Brasil. Edited by Arilha M, Souza Lapa T, Crenn Pisaneschi T. São Paulo: Comissão de Cidadania e Reprodução; 2010. Coleção Democracia, Estado Laico e Direcitos Humanos
• [14]Gynuity Health Projects: Map of Misoprostol Approval. 2011. http://gynuity.org/resources/info/map-of-misoprostol-approval/ webcite
• [15]ANMAT, Ministerio de Salud, Secretaría de Políticas Regulación e InstitutosDisposición N° 6291 (October 15, 2010). http://www.anmat.gov.ar/boletin_anmat/octubre_2010/Dispo_6291-10.pdf webcite
• [16]Távara Orozco L, Chávez S, Grossman D, Lara D, Blandon MM: Disponibilidad y Uso Obstétrico del Misoprostol en los Países de América Latina y el Caribe. Lima: CLACAI; 2011.
• [17]Lafaurie MM, Grossman D, Troncoso E, Billings D, Chávez Alvarado S, Maira G, et al.: El Aborto con Medicamentos en América Latina. Las Experiencias de las Mujeres en México, Colombia, Ecuador y Perú. Population Council y Gynuity Health Projects; 2005.
• [18]Lafaurie MM, Grossman D, Troncoso E, Billings D, Chávez S: Women's perspectives on medical abortion in Mexico, Colombia, Ecuador and Peru: A qualitative study. Reprod Health Matters 2005, 3:75-83.
• [19]Colectiva por la Libre Información para las Mujeres (CLIM): Primer Reporte Político a un Año de Funcionamiento de la Línea Aborto Información Segura. Lima: Perú; May 2010-June 2011
• [20]Billings D, Walker D: Mainero del Paso G, Andersen Clark C, Deyananda I: Pharmacy worker practices related to misoprostol for abortion in one Mexican state. Contraception 2009, 79:56-64.
• [21]Lara D, Grossman D, Díaz-Olavarrieta C: Pharmacy provision of medical abortifacients in a Latin American City. Contraception 2006, 74:394-399.
• [22]Zamberlin N, Gianni MC: El circuito del misoprostol: un estudio de las respuestas a la demanda de medicamentos abortivos en farmacias privadas. Rev Med 2007(67 Suppl I):67.
• [23]Lara D, García S, Wilson K, Paz F: How often and under which circumstances do Mexican pharmacy vendors recommend misoprostol to induce abortion. Int Perspect Sex Reprod Health June 2011, 37(2):75-83.
• [24]Vázquez S, Gutiérrez MA, Calandra N, Berner E: El aborto en la adolescencia. Investigación sobre el uso de misoprostol para la interrupción del embarazo en adolescentes. In Realidades y Coyunturas del Aborto. Entre el Derecho y la Necesidad. Edited by Checa S. Buenos Aires: Paidós; 2008:277-297.
• [25]Carril Berro E, López Gómez A: Entre el Alivio y el Dolor: Mujeres, Aborto Voluntario y Subjetividad. Montevideo: Trilce; 2008.
• [26]Chávez S, Britt-Coe A: El aborto médico desde la perspectiva de un grupo de mujeres atendidas en un servicio atendido por consejeras en un distrito populoso de Lima. Lima: Promsex; 2002.
• [27]Briozzo L, Vidiella G, Rodríguez F, Gorgoroso M, Faundes A, Pons JE: A risk reduction strategy to prevent maternal deaths associated with unsafe abortion. Int J Gynecol Obstet 2006, 95:221-226.
• [28]Miller S, Lehman T, Campbell M, Hemmerling A, Anderson SB, Rodriguez H, et al.: Misoprostol and declining abortion-related morbidity in Santo Domingo, Dominican Republic: a temporal association. BJOG 2005, 112:1291-1296.
• [29]Faundes A, Santos LC, Carvalho M, Gras C: Post-abortion complications after interruption of pregnancy with misoprostol. Adv Contracept 1996, 2:1-9.
• [30]Sherris J, Bingham A, Burns MA, Girvin S, Westley E, Gomez PI: Misoprostol use in developing countries: results from a multicountry study. Int J Gynecol Obstet 2005, 88:76-81.
• [31]Harper CC, Blanchard K, Grossman D, Henderson JT, Darney PD: Reducing maternal mortality due to elective abortion: Potential impact of misoprostol in low-resource settings. Int J Gynecol Obstet 2007, 98:66-69.
• [32]Donoso E: Mortalidad materna en Chile, 2000–2004. Rev Chil Obstet Ginecol 2006, 71:246-251.
• [33]Lie M, Robson S, May C: Experiences of abortion: A narrative review of qualitative studies. BMC Health Serv Res 2008, 8:150. BioMed Central Full Text
• [34]Costa SH: Commercial availability of misoprostol and induced abortion in Brazil. Int J Gynecol Obstet 1998, 63(Suppl 1):131-139.
• [35]Costa SH, Vessey MP: Misoprostol and illegal abortion in Rio de Janeiro. Lancet 1993, 341:1258-1261.
• [36]Osava R, Amorim MH, Castro D, Marques M: Perfil reprodutivo e padröes de consumo do misoprostol (Cytotec) como droga abortiva em usuárias de baixa renda. Revista Enfermagen UERJ 1997, 5:325-330.
• [37]Coelho HL, Texeira AC, Santos AP, Barros Forte E, Macedo Morais S, La Vecchia C, et al.: Misoprostol and illegal abortion in Fortaleza, Brazil. Lancet 1993, 341:1261-1263.
• [38]Coêlho HL, Teixeira AC, Cruz Mde F, Gonzaga SL, Arrais PS, Luchini L, et al.: Misoprostol: The experience of women in Fortaleza, Brazil. Contraception 1994, 49:101.
• [39]Maroto Vargas A: Al Amparo de la Noche. La Ruta Crítica de las Mujeres que se Realizan Abortos Clandestinos en Costa Rica. San José de Costa Rica: Asociación Colectiva por el Derecho a Decidir; 2010.
• [40]Troncoso E, Gómez Ponce de León R, Suárez C: Panorama del Aborto con Medicamentos: Resultados de Diagnósticos en 5 Países de América Latina en 2006. Chapel Hill: IPAS; 2007.
• [41]Gould H, Ellerston C, Corona G: Knowledge and attitudes about emergency contraception and medical abortion among middle-class women and men of reproductive age in Mexico City. Contraception 2002, 66:417-426.
• [42]Ramos S, Viladrich A: Abortos Hospitalizados. Entrada y Salida de Emergencia. Buenos Aires: CEDES; 1993.
• [43]Pedrosa IL, Garcia TR: Não vou esquecer nunca!: A experiência feminina com o abortamento induzido. Rev Lat Am Enfermagem 2000, 8:50-58.
• [44]Billings D: Misoprostol alone for early medical abortion in a Latin American clinic setting. Reprod Health Matters 2004, 12(Suppl):57-64.
• [45]Carril Berro E, López Gómez A: Varones y aborto voluntario: Significados y opiniones en varones de distintas generaciones y niveles educativos. Cátedra Libre en Salud Reproductiva, Sexualidad y Género, Facultad de Psicología; Universidad de la República, Uruguay. Technical Report 2008.
• [46]Petracci M, Pecheny M, Capriati A, Mattioli M: Varones, aborto y trayectorias socioafectivas según las experiencias y relatos de varones y mujeres de Buenos Aires, Argentina. In Proceedings of the VIII Reunión de Antropología del Mercosur: Diversidad y Poder en América Latina. Buenos Aires: UNSAM; 2009.
• [47]Rance S: Entre ellos saben: Género y poder en relatos de mujeres bolivianas sobre sus experiencias con el aborto medicamentoso. In Proceedings of the Conferencia Latinoamericana sobre Prevención y Atención del Aborto Inseguro: 29–30 June 2009. Lima: CLACAI;
• [48]Berer M: Why medical abortion is important for women. Reprod Health Matters 2005, 13:6-10.
• [49]Chaneton J, Vacarezza N: La Intemperie y lo Intempestivo. Experiencias del Aborto Voluntario en el Relato de Mujeres y Varones. Buenos Aires: Marea Editorial; 2011.
• [50]Pazello M: Internet, restrição de informações e acesso ao misoprostol. In Aborto Medicamentoso no Brasil. Edited by Arilha M, Souza Lapa T, Crenn Pisaneschi T. São Paulo: Oficina Editorial, Comissão de Cidadania e Reprodução; 2010.
• [51]Araujo MJ: O uso do misoprostol pelas mulheres. In Direitos Reprodutivos no Brasil. Trilhas de Saúde das Mulheres, dos Direitos Sexuais e Dereitos Reprodutivos, Caderno 01. Porto Alegre: Rede Feminista de Saúde; 2010.
• [52]Ouvinha Peres S, Heilborn ML: Cogitação e prática do aborto entre jovens em contexto de interdição legal: o avesso da gravidez na adolescência. Cad Saude Publica 2006, 22:1411-1420.
• [53]Beca Ramón Carrillo-Arturo Oñativia, CONAPRIS/Ministerio de Salud y Ambiente de la Nación: Informe Final proyecto multicéntrico Morbilidad materna severa: prevención y calidad de la atención del aborto para reducir su incidencia y consecuencias adversas. CEDES-CENEP-Maimónides; 2005–2006
• [54]Fonseca W, et al.: Características sócio-demográficas, reprodutivas e médicas de mulheres admitidas por aborto em hospital da Região Sul do Brasil. Cad Saude Publica 1998, 14:279-286.
• [55]Israel E, Sanhueza P, Lucero P, Ulloa C: Muerte materna debida a intoxicación por sobredosis de misoprostol intravaginal. Rev Chil Obstet Ginecol 1998, 63:125-128.
• [56]Pedroso D, de Campos Gomez E, Drezzet J: Abortamento previsto em lei em situacoes de violencia sexual. Perspectivas e experiencias das mulheres. In Magnitude do Aborto no Brasil. Aspectos Epidemiológicos e Socio-culturais. Edited by Adesse L, Monteiro M. Rio de Janeiro: IPAS; 2007.
• [57]Winikoff B: Acceptability of medical abortion in early pregnancy. Fam Plann Perspect 1995., 27July/Aug
• [58]Elul B, Pearlman E, Sorhaindo A, Simonds W, Westhoff C: In depth interviews with medical abortion clients: thoughts on the method and home administration of misoprostol. JAMWA 2000, 55(3):169-172.
• [59]Fielding S, Edmunds E, Schaff E: Having an abortion using mifepristone and home misoprostol: A qualitative analysis of women's experiences. Perspect Sex Reprod Health 2002 Jan-Feb, 34:34-40.
• [60]Kulczycki A: Abortion in Latin America: Changes in practice, growing conflict, and recent policy developments. Stud Fam Plann 2011, 42:199-220.
• [61]Guillaume A, Lerner S: Abortion in Latin America and the Caribbean. A Review of Literature from 1990 to 2005. Paris/Mexico: CEPED-Population Council; 2007.
• [62]Duarte Osis MJ, Hardy E, Faundes A, Rodrigues T: Dificultades para obter informações da população de mulheres sobre aborto ilegal. Rev Saude Publica 1996, 30:444-451.
• [63]Goel S, Salganik MJ: Assessing respondent-driven sampling. Proceedings of the National Academy of Science 2010, 107(15):6743-6747.
• [64]Gomperts RJ, Jelinska K, Davies S, Gemzell-Danielsson K, Kleiverda G: Using telemedicine for terminantion of pregnancy with mifepristone and misoprostol in settings where there is no access to safe services. BJOG 2008, 115:1171-1178.
• [65]Zamberlin N, Raiher S: Revisión del conocimiento disponible sobre experiencia de las mujeres con el uso del misoprostol en América Latina. Buenos Aires: Consorcio Latinoamericano contra el Aborto Inseguro/Centro de Estudios de Estado y Sociedad; 2010.